Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks Article

sustainable development goals

publication date

  • November 1, 2025

webpage

published in